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There is increasing evidence that the aberrant immune 
response in the lungs instigated by the severe acute respira-
tory syndrome coronavirus 2 (SARS-COV-2) leads to lung 
scarring and fibrosis.1 This ranges from fibrosis associated 
with organizing pneumonia to more severe lung injury, with 
widespread fibrotic change.2 Lung fibrosis is observed in 
almost all fatal cases of COVID-19.3 Furthermore, there is 
a high rate of interstitial lung function abnormalities in 
COVID-19 patients discharged from the hospital, with 47% 
(of 110 patients studied) showing impaired gas transfer and 
25% showing reduced total lung capacity.4 The degree of 
this lung function compromise may have an important 
impact on the long-term recovery and prognosis of COVID-
19 survivors. Data from similar conditions including SARS, 
Middle East respiratory syndrome (MERS), and subsets of 
acute respiratory distress syndrome (ARDS) show that 
patients all develop lung fibrosis, with greater fibrosis 
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Assay Utilizing Primary Human Lung 
Fibroblasts to Identify Antifibrotic Drugs  
for Rapid Repurposing in COVID-19 Patients
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Abstract
Lung imaging and autopsy reports among COVID-19 patients show elevated lung scarring (fibrosis). Early data from 
COVID-19 patients as well as previous studies from severe acute respiratory syndrome, Middle East respiratory syndrome, 
and other respiratory disorders show that the extent of lung fibrosis is associated with a higher mortality, prolonged 
ventilator dependence, and poorer long-term health prognosis. Current treatments to halt or reverse lung fibrosis are 
limited; thus, the rapid development of effective antifibrotic therapies is a major global medical need that will continue 
far beyond the current COVID-19 pandemic. Reproducible fibrosis screening assays with high signal-to-noise ratios and 
disease-relevant readouts such as extracellular matrix (ECM) deposition (the hallmark of fibrosis) are integral to any 
antifibrotic therapeutic development. Therefore, we have established an automated high-throughput and high-content 
primary screening assay measuring transforming growth factor-β (TGFβ)-induced ECM deposition from primary human 
lung fibroblasts in a 384-well format. This assay combines longitudinal live cell imaging with multiparametric high-content 
analysis of ECM deposition. Using this assay, we have screened a library of 2743 small molecules representing approved 
drugs and late-stage clinical candidates. Confirmed hits were subsequently profiled through a suite of secondary lung 
fibroblast phenotypic screening assays quantifying cell differentiation, proliferation, migration, and apoptosis. In silico target 
prediction and pathway network analysis were applied to the confirmed hits. We anticipate this suite of assays and data 
analysis tools will aid the identification of new treatments to mitigate against lung fibrosis associated with COVID-19 and 
other fibrotic diseases.
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associated with prolonged ventilator dependence, higher 
mortality rate, and poorer prognosis in long-term health-
related quality of life.5–8
The precise cellular and molecular mechanisms that 
underpin lung fibrosis in diseases like idiopathic lung fibro-
sis (IPF) remain unclear. This in turn hinders the design of 
appropriate preclinical models with which to investigate the 
diseases for drug discovery and the identification of the most 
effective therapeutic targets. However, what is clear from 
pathology studies in lung fibrosis patients is the common 
occurrence of fibroproliferation with associated aberrant 
deposition of extracellular matrix (ECM) within the lung, 
leading to impaired gas exchange and lung function that can 
be progressive and terminal.9 Therefore, targeting fibroblast 
“fibroproliferation” and associated ECM deposition as 
adjunctive interventions to immunosuppressive therapies 
represents a logical therapeutic strategy for both delaying 
disease onset and, potentially, reversal of disease pathology.
There are only two drugs approved for specifically treat-
ing IPF—pirfenidone and nintedanib. These have proven 
partially effective at controlling lung diseases such as IPF, 
and studies are ongoing as to their effectiveness toward the 
fibroproliferative response in COVID-19.1 Due to so few 
current antifibrotic therapies available and the substantial 
risk of increased incidence of lung fibrosis post-COVID-19 
infection, there is a critical need for further investment in 
improved drug discovery screening cascades that incorpo-
rate more relevant and informative laboratory models of 
lung fibrosis. The application of target-agnostic phenotypic 
assays with multiple readouts is well placed to provide 
improved hit rates for potential antifibrotic therapies via the 
empirical identification of novel drug candidates or repur-
posed drugs that target distinct pathway mechanisms.
To help innovate the identification of novel targets, new 
chemical starting points, and potential drug repurposing can-
didates for tackling lung fibrosis, we established an auto-
mated high-throughput and high-content assay measuring 
primary human lung fibroblast proliferation and ECM depo-
sition. To rapidly repurpose drugs toward clinical trials for 
the treatment of patients with or recovering from COVID-19, 
we prioritized the screening of a library of 2743 small mole-
cules predominantly composed of approved drugs and late-
stage clinical candidates. Here, we describe the development 
and application of our primary high-content screen and a 
suite of image-based secondary lung phenotypic assays to 
mechanistically profile and triage those hits that may have 
greatest value in preventing, halting, or reversing lung fibro-
sis in patients with COVID-19. We identify the following six 
drugs, which demonstrate potent and reproducible activity in 
our lung phenotypic assays: RepSox, camptothecin, diphen-
ylene-iodonium chloride, GSK-650394, niclosamide, and 
fenretinide. We further describe how combining multipara-
metric high-content image analysis, structural similarity 
ligand-based target prediction, and pathway network analysis 
deconvolutes the mechanism of action of our phenotypic hits 
at the target and pathway network level. We present full 
results from our screening assays and assay protocols to sup-
port the identification of new potential therapies to reduce 
aberrant pulmonary fibrosis in COVID-19 patients and other 
lung diseases.
Materials and Methods
Primary Human Lung Fibroblast Culture
Primary human lung fibroblasts from healthy donors 
(American Type Culture Collection [ATCC], Manassas, 
VA, PCS-201-013) were expanded by three passages (21 
days in culture), followed by cryopreservation as assay-
ready stocks. Fibroblast culture was performed using fibro-
blast growth medium-2 (FGM-2) BulletKit media (Lonza, 
CC-3132, Slough, UK) under standard tissue culture condi-
tions (37 °C and 5% CO2). Fibroblasts were harvested by 
washing twice with Dulbecco’s phosphate-buffered saline 
(DPBS) (Thermo Fisher Scientific, Waltham, MA) incu-
bated with TrypLE Express (Thermo Fisher Scientfic) at 
37 °C for 4 min, diluted using FGM-2 BulletKit media and 
centrifuged for 5 min at 200g. The cells were resuspended 
in either FGM-2 BulletKit media for continued passage or 
cryopreservation, or Renal Epithelial Cell Basal Medium 
(ATCC, PCS-400-030) supplemented with Renal Epithelial 
Cell Growth Kit (ATCC, PCS-400-040) for high-content 
compound screening. Cell counts were performed using a 
NucleoCounter NC-100 with NucleoCassettes per the man-
ufacturer’s protocol (Chemometec, Allerod, Denmark).
High-Content ECM Deposition Assay
Fibroblasts were resuspended in treatment media at 80,000 
cells/mL and then seeded into 384-well imaging plates 
(Greiner microclear, Greiner Bio-One GmbH, Kremsmunster, 
Austria) at 25 µL/well, with a further 25 µL of media with or 
without 10 ng/mL rhTGFβ (R&D Systems, Minneapolis, 
MN, 7754-BH/CF; final concentration, 5 ng/mL). The plates 
were given a pulse spin (200g for 1 s) and then placed in an 
incubator overnight. The following day, the compounds (1 
µM) or DMSO control (0.1% v/v) were added using a 
BioMek liquid handling unit (Beckman Coulter, Brea, CA). 
Compound libraries included the Prestwick Chemical Library 
(Prestwick Chemical, Illkirch, France) and LOPAC1280 
(Library of Pharmacologically Active Compounds; Merck, 
Darmstadt, Germany). The plates were then placed into the 
IncuCyte Live Cell Imaging System (Sartorius, Gottingen, 
Germany) and imaged every 3 h for 6 days.
ECM was stained using a protocol adapted from 
Holdsworth et al.10 Briefly, the cells were lysed using an 
ammonia-based lysis media (0.25 M NH4OH, 25 mM Tris) 
for 30 min at 37 °C, followed by washing three times with 
phosphate-buffered saline (PBS). The ECM was fixed using 
ice-cold methanol for 20 min at –20 °C, followed by 
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washing three times with PBS. Assay plates were then 
blocked using 1% (v/v) goat serum (G9023, Thermo Fisher 
Scientific) in PBS for 45 min, followed by labeling with 
anti-collagen I (Millipore, Burlington, MA, AB745; 1 in 
100), anti-collagen III (Millipore, AB747; 1 in 100), and 
anti-collagen IV (Ebioscience, San Diego, CA, 14-9871-82; 
Millipore; 1 in 100) antibodies diluted in blocking buffer 
for 1.5 h, followed by three washes with PBS. The cells 
were then incubated with Alexa Fluor 555 Goat anti-Rabbit 
IgG (Life Technologies, Carlsbad, CA, A21430; 1 in 400) 
and Alexa Fluor 647 Goat Anti-Mouse IgG (Life 
Technologies, A21236; 1 in 400) for 1.5 h, followed by 
washing three times with PBS. The cells were then labeled 
with Alexa Fluor 488 anti-fibronectin (Ebioscience, 
53-9869-82; 1 in 400) for 1.5 h, followed by washing three 
times with PBS and stored in the dark at 4 °C.
High-Content ECM Deposition Assay:  
Image Acquisition and Analysis
Plates were imaged on an ImageXpress high-content micro-
scope (Molecular Devices, San Jose, CA) using a 10× objec-
tive capturing four fields of view per well. ECM deposition 
was measured using a custom analysis created in the Custom 
Module Editor (MetaXpress, Molecular Devices). Briefly, a 
mask for each fluorescent channel containing ECM was cal-
culated by selecting a user-defined threshold. All three ECM 
component masks (collagen I+III, collagen IV, and fibronec-
tin) were combined to form a “total ECM mask” against 
which the intensity of the fluorescent antibody labeling in 
each individual channel could be measured. Image-level data 
were aggregated using the SUM function, exported, and ana-
lyzed using HC StratoMineR software (Core Life Analytics, 
‘s-Hertogenbosch, Netherlands). Briefly, data were normal-
ized to percentage inhibition of transforming growth factor-β 
(TGFβ)-induced ECM deposition and scaled using a robust Z 
score. Hit compounds were selected using a Euclidean dis-
tance from the negative control with a p value cutoff of 0.05 
(corrected using the false discovery rate).
Primary Lung Fibroblast αSMA Expression  
and Proliferation Assay
Primary human lung fibroblasts were plated, TGFβ stimu-
lated, and drug treated in 384-well plates as per the ECM 
deposition assay. An untreated plate was also cultured over-
night, fixed, and labeled with HCS CellMask Green 
(Invitrogen, Themo Fisher Scientific, H32714) and Hoechst 
33342 (Invitrogen, R37605) for a cell count at day 1. Plates 
were drug treated for 6 days and then fixed using 4% form-
aldehyde (Pierce, 28906) in PBS for 15 min at 37 °C, fol-
lowed by three washes with PBS. Day 1 and drug-treated 
plates were permeabilized with 0.1% Triton X-100 in PBS 
(Thermo Fisher Scientific, 28313) for 10 min, followed by 
two washes with PBS, followed by blocking (10% goat 
serum, 1% bovine serum albumin [BSA], 0.3 M glycine in 
PBS with 0.1% Tween) for 45 min. The cells were then 
labeled with anti-α-smooth muscle actin (anti-αSMA) 
(Abcam, Cambridge, UK, ab7817; 1 in 200) diluted in 1% 
BSA in PBS/0.1% Tween) overnight. Plates were washed 
three times with PBS and labeled with Alexa Fluor 647 anti-
mouse secondary antibody (Thermo Fisher Scientific, 
A-21236; 1 in 400) diluted in 1% BSA-PBS/0.1% Tween 
for 1.5 h. Plates were washed three times in PBS and labeled 
with HCS CellMask Green (1 in 20,000) and Hoechst 33342 
(1 in 15) in PBS for 30 min and finally washed three times 
with PBS. The plates were then stored in the dark prior to 
image acquisition using a 10× objective on the ImageXpress 
(Molecular Devices).
The expression of αSMA was measured with a custom 
analysis using the Custom Module Editor (MetaXpress, 
Molecular Devices). Briefly, Hoechst 33342 labeling was 
used to create a nuclei mask identified with a user-defined 
threshold. The nuclei mask was then used to identify cyto-
plasmic fluorescence for each cell and to generate a mask 
for αSMA and HSC CellMask Green labeling with a user-
defined threshold. Nuclei, αSMA, and HCS CellMask 
Green masks were combined to create a whole-cell mask 
that was used to measure the integrated intensity of each 
individual component.
Scratch Wound Migration Assay
The scratch wound assay was performed and imaged using 
the IncuCyte Zoom Live Cell Imaging System and Scratch 
Wound analysis module per the manufacturer’s instructions 
(IncuCyte, Sartorius). Briefly, human lung fibroblasts were 
resuspended in treatment media with 5 ng/mL TGFβ at 
150,000 cells/mL, and cells were seeded in 96-well plates at 
a final density of 15,000 cells/well (Corning, New York, 
NY) and incubated overnight. The following day, scratch 
wounds were performed using the IncuCyte WoundMaker 
as previously described.11 The media was then replaced to 
remove cell debris, compounds were added, and the plate 
was imaged every 2 h using the IncuCyte for 4 days. Wound 
closure was calculated using IncuCyte’s wound confluence 
analysis module for each image over time.
Apoptosis Assay
Human lung fibroblasts were resuspended in treatment 
media with 5 ng/mL TGFβ at 40,000 per milliliter and then 
seeded into 384-well imaging plates (Greiner, 781091) at 25 
µL/well. The plates were given a pulse spin (200g for 1 s) 
and then placed in an incubator overnight. The following 
day, the compounds or DMSO (0.1% v/v final concentra-
tion) control were added, followed by an apoptosis reporter 
(IncuCyte Caspase 3/7 Green; Sartorius, 4440; 5 µM), as 
previously described.12 The plates were then imaged every 
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2 h for 48 h in an IncuCyte Live Cell Imaging System. 
Apoptotic cells were identified using the IncuCyte’s analy-
sis software to count the caspase 3/7-positive (green) cells 
in each image.
Hit Confirmation Concentration Response  
and EC50 Determination
The 32 primary assay hit compounds were reordered from 
new commercial suppliers (MolPort, Riga, Latvia) and hit 
confirmation dose response plates were prepared as a 
10-point semi-log concentration and added to the primary 
high-content ECM deposition assay at a final concentration 
of between 10 µM and 0.3 nM. ECM deposition was ana-
lyzed as described above, and EC50 values for compounds 
across each ECM channel were calculated by fitting the con-
centration response data to a standard four-parameter equa-
tion using Prism software (GraphPad, San Diego, CA). The 
top six potent compounds were also tested using a 10-point 
semi-log concentration range in the secondary lung fibro-
blast phenotypic profiling assays: αSMA expression, prolif-
eration, apoptosis, and scratch wound migration.
Structural Similarity Ligand-Based  
Target Predictions (SEA Search)
A structure-based in silico search of hit molecules was car-
ried out using the publicly available, online resource 
Similarity Ensemble Approach (SEA) search (http://sea.
bkslab.org).13 A SMILES string of each molecule (from 
Prestwick and LOPAC data files) was pasted into the SEA 
search fields. The SEA output includes a ranking of the pro-
posed target/query interaction by probability and similarity 
score (Tanimoto coefficient). Significant predictions were 
further investigated via the ZINC database14 and links to 
other chemo-resources.
Network Analysis
Network analysis was performed using Cytoscape v3.8.2.15 
Protein targets of hit compounds were identified using the 
STITCH-STRING app (v1.6.0)16 to retrieve protein–com-
pound and protein–protein interactions using a confidence 
score cutoff of 0.4 with up to 30 additional interactions. 
Functional analysis of hit compound–protein networks was 
analyzed using the ClueGO app v2.5.717 showing only sig-
nificant REACTOME pathways (p < 0.05). SEA search 
predictions were manually added to the networks.
Results
Assay Development: High-Content Primary  
Lung Fibroblast ECM Deposition Assay
Primary human lung fibroblasts become increasingly sensi-
tive to cryopreservation and senescence after repeated 
subculture, which can affect assay reproducibility across 
sequential cell culture passages. To mitigate this for our 
suite of primary human lung pro-fibrotic assays, original 
fibroblast stocks (ATCC, PCS-201-013) were rapidly 
expanded over three passages (no more than 21 days in cul-
ture in total) before being cryopreserved as assay-ready 
stocks. All assays were performed directly from these stocks 
with no further subpassaging between assays, which pro-
vided a foundation of cell phenotype reproducibility from 
which the assays could be performed. The density of pri-
mary human lung fibroblasts in culture greatly affects their 
phenotypic responses and particularly their susceptibility to 
compound toxicity. Accurate cell counting is therefore also 
an issue with primary human fibroblasts assays as they form 
tight clumps in suspension. This was mitigated by using a 
NucleoCounter (Chemometec), which performs a cytoplas-
mic lysis before counting stained nuclei, allowing consis-
tent seeding densities between assays and across screens. 
For our 384-well high-content ECM deposition assays, a 
seeding density of 2000 cells/well was determined to be 
optimal. We have established and describe our full lung pro-
fibrotic assay cascade, including the primary screen of 
human lung fibroblast ECM deposition with parallel live 
cell imaging, secondary phenotypic assays, and in silico hit 
target prediction and pathway network analysis (Fig. 1A).
As ECM deposition is a cell-free endpoint, it is difficult 
to triage compound hits in terms of compound cytotoxicity. 
If there is no or a significant reduction in ECM, without cell 
information it would be impossible to determine if this was 
due to specific inhibition of ECM synthesis, secretion and 
deposition, or simply significant lung fibroblast cytotoxicity 
of the compound. Therefore, to identify cytotoxic com-
pounds, all assay plates were monitored by live cell imaging 
every 3 hours using an IncuCyte Zoom microscope during 
the course of the assay and immediately prior to cell lysis 
and ECM deposition labeling. Live cell imaging of assay 
plates therefore provided longitudinal phenotypic assess-
ment of cell health following compound treatment for direct 
correlation with ECM deposition and the ability to triage the 
clearly cytotoxic compound hits from the screen (Fig. 1B).
Fibroblasts do not readily deposit ECM when cultured in 
proprietary fibroblast growth media, which is formulated to 
maintain a proliferative state, rather than allow a myofibro-
blast-like terminal differentiation that is necessary for ECM 
deposition. Therefore, all assays were run using renal proxi-
mal tube epithelial cell (RPTEC) media which Holdsworth 
et al.10 previously showed to enable reproducible mature 
ECM deposition from lung fibroblasts upon stimulation with 
TGFβ. Following immunolabeling of the ECM components 
(fibronectin and collagen types I, III, and IV) (Fig. 1C), 
imaging of the ECM was performed using an ImageXpress 
high-content imaging system and images analyzed using a 
custom module in MetaXpress software. We used untreated 
cells (no TGFβ) as a negative control to compare the ECM 
deposition induced by 5 ng/mL TGFβ. Following a series of 
time course and concentration–response curves, an optimal 
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Figure 1. ECM and triage assay workflow. (A) Workflow for screening compounds through the ECM and triage assays.  
(B) Representative images from live cell imaging showing viable cells (top) and cell death (bottom) induced by compound  
cytotoxicity. (C) Representative high-content images of fibronectin, collagen I+III, and collagen IV staining with composite image.  
(D) Representative full-plate montage images showing fibronectin staining with or without TGFβ (5 ng/mL) to assess the assay 
window between minimum and maximum ECM deposition (left) and TGFβ (5 ng/mL)-induced fibronectin staining across a full 384-
well plate for coefficient of variance assessment (right).
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concentration of 5 ng/mL TGFβ for 7 days was identified as 
the optimal assay condition to induce reproducible ECM 
deposition. Intraplate coefficient of variance values for 
fibronectin (12.9%), collagen I+III (14.8%), and collagen 
IV (16.6%) demonstrate good assay reproducibility follow-
ing TGFβ stimulation of ECM deposition (Fig. 1D).
High-Content Primary Lung Fibroblast  
ECM Deposition Assay
Small-Molecule High-Content Screen. A compound library of 
2743 small molecules was screened at a single concentration 
of 1 µM in the ECM deposition assay. This library comprised 
the commercially available Prestwick Chemical Library of 
1280 mostly off-patent Food and Drug Administration- and 
European Medicines Agency-approved compounds, the 
LOPAC library (1280 compounds), the Enzo SCREEN-
WELL chemogenomic library of 176 epigenetic protease and 
kinase inhibitors, and a small selection of compounds of 
interest from collaborators. In brief, primary human lung 
fibroblasts were automatically dispensed into a 384-well 
plate in the presence of the inflammatory stimulus TGFβ (5 
ng/mL) to induce ECM production. Twenty-four hours after 
cell plating, compounds were automatically dispensed at a 
final concentration of 1 µM using a Biomek FX. Following 
compound addition, cell assay plates were monitored in the 
IncuCyte Live Cell Imaging System, prior to cell lysis, fixa-
tion, and ECM labeling after 6 days of compound treatment 
(Fig. 1) (see Materials and Methods for further details). Con-
trol wells of lung fibroblasts ± TGFβ stimulation (32 wells 
of each) were included on each assay plate (Fig. 2A). Images 
of ECM deposition across assay plates were automatically 
acquired on an ImageXpress high-content platform (Molecu-
lar Devices) integrated with Peak Analysis and Automation 
plate handling robotics (PAA, Farnborough, UK). The fluo-
rescent intensity of the ECM deposited in each image was 
measured and data were analyzed using the HC StratoMineR 
analysis software. Briefly, data were normalized on a per 
plate basis as percentage inhibition of TGFβ-induced ECM 
deposition. This analysis gave an overall hit rate of 10.6% 
(292 compounds) (Fig. 2B). The high hit rate is partly due to 
cytotoxic compounds, which simply reduced the ECM end-
point by killing the cells rather than inducing a specific phe-
notypic change. To filter out overtly cytotoxic compounds 
from the primary hit selection, cell confluence was calculated 
from the IncuCyte live cell images collected at day 6 of the 
assay. The live cell images from active compounds with less 
than 50% confluence at day 6 were then visually assessed to 
confirm cytotoxicity and then removed from the hit list. In 
total, 32 hit compounds from the ECM high-content analysis 
with no evidence of overt cytotoxicity (Fig. 3A) were selected 
for hit confirmation studies.
Hit Confirmation Assay: 10-Point Concentration Response. The 
32 compounds prioritized from the primary screen were 
reordered from different commercial compound suppliers 
and retested across a 10-point semi-log concentration range 
using the high-content ECM deposition assay (Fig. 3). Here, 
14 of the 32 compounds demonstrated some activity upon 
reducing ECM deposition in the assay at the top two concen-
trations of 10 and 3 µM (Fig. 3A). The following six com-
pounds demonstrated the most potent concentration-dependent 
activity in reducing ECM deposition: RepSox, camptothecin, 
diphenylene-iodonium chloride, GSK-650394, niclosamide, 
and fenretinide. EC50 values for the reduction of ECM 
deposition were calculated to be in the range of 38.6 nM– 
4.2 µM (Fig. 3B and Suppl. Figs. S1–S3). The results of 
compound activity on deposition of collagen types I, III, 
and IV and representative live cell images 6 days following 
compound treatments are shown in Supplemental Figures 
S1–S3. Validated hit compounds were assessed for cytotox-
icity by reviewing the live cell images at day 6 post-com-
pound addition, and each concentration was annotated as to 
whether cytotoxic activity was observed (Fig. 3B and 
Suppl. Figs. S1–S3). RepSox is a selective and potent 
inhibitor of the TGFβ type 1 receptor (TGFβRI) ALK5 and, 
as expected, inhibited TGFβ-induced deposition of ECM in 
this assay (Fig. 3B and Suppl. Fig. S1) (collagen I+III, 
EC50 = 38.6 nM; collagen IV, EC50 = 58.7 nM; fibronec-
tin, EC50 = 119 nM). While TGFβ remains an important 
target in fibrosis, RepSox was also judged to be a useful 
assay control for future phenotypic screens, as it not only 
blocked the deposition of ECM but also did so with no 
effect on cell death. RepSox was also taken forward as a 
comparator for the other more novel hit compounds in sec-
ondary assays.
Secondary Hit Triage and Compound  
Profiling Assays
The six most potent compounds confirmed by the 10-point 
semi-log concentration response studies were taken forward 
into four further secondary assays to assess the activity of 
each compound on key areas of fibroblast biology: (1) 
fibroblast to myofibroblast differentiation using the expres-
sion of αSMA as a marker, (2) primary lung fibroblast pro-
liferation (nuclear count), (3) apoptosis of lung fibroblasts 
using a caspase 3/7 biosensor, and (4) lung fibroblast wound 
healing using a scratch wound migration assay.
αSMA Expression and Cell Proliferation. The induction of 
αSMA is integral for fibroblast to myofibroblast differenti-
ation and is often associated with subsequent deposition of 
ECM. We therefore established a screening assay to simul-
taneously evaluate the effect of the six most potent hits 
from the ECM deposition assay upon αSMA expression 
and proliferation in primary human fibroblasts (Fig. 4A). 
The assay setup and compound treatment mirrored the 
ECM assay. Briefly, primary lung fibroblasts were plated 
subconfluently in RPTEC media in 384-well plates and 
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treated with TGFβ (5 ng/nL) for positive control or without 
TGFβ for negative control. Drug treatments were added in 
the presence of the inflammatory stimulus TGFβ. αSMA 
actin induction could be observed on day 4 but was most 
uniform by day 7; therefore, the assay was analyzed on day 
7. Briefly, plates were fixed and labeled with anti-αSMA 
antibody, Hoechst 33342, and HCS CellMask green and 
imaged on an ImageXpress (Molecular Devices) as 
described in Materials and Methods. The expression of 
αSMA was reduced by all six compounds in a concentra-
tion-dependent manner similar to the reduction in ECM 
deposition seen with each compound (Fig. 4A).
Primary Human Lung Fibroblast Proliferation. Primary human 
lung fibroblasts were dispensed into duplicate 384-well 
plates. One plate was fixed and labeled with Hoechst 33342 
on day 1 (24 h after plating) prior to compound addition to 
provide a cell number baseline to compare with the cell 
number following 6 days of compound addition. Cell 
proliferation was estimated by subtracting the nuclei counts 
from the day 1 baseline from day 6 values and was normal-
ized to a percentage of the TGFβ positive control. Prolifera-
tion of the fibroblasts was elevated by all the compounds at 
lower concentrations (below 1 µM) with the exception of 
camptothecin, which significantly reduced the lung fibro-
blast cell number in a concentration-dependent manner 
(Fig. 4B). Elevated proliferation induced by RepSox, 
diphenylene-iodonium chloride, GSK-650394, niclosamide, 
and fenretinide at lower doses agrees with the reduction in 
fibroblast differentiation (αSMA-positive cells), suggesting 
that the hit compounds likely reduce the TGFβ-induced ter-
minal differentiation to myofibroblasts, and consequently 
have a higher proliferative phenotype than the TGFβ-
stimulated control fibroblasts.
Induction of Apoptosis in Primary Lung Fibroblasts. Primary 
human lung fibroblasts were seeded in 384-well plates, com-
pound treated the following day, and the induction of 
Figure 2. Primary human lung fibroblast ECM deposition high-content screen. Primary human lung fibroblasts were treated 
with TGFβ (5 ng/mL) over 7 days in the presence of compounds (1 µM). Plates were denuded of cells and ECM components 
immunolabeled and imaged on an ImageXpress microscope. (A) Exemplar images of ECM deposition. (B) Principal component (PC) 
analysis of the quantification of ECM deposition in response to compound treatment. (C) Hit classification using a Euclidean distance 
from the negative control with a p value cutoff of 0.05 (corrected using the false discovery rate).
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Figure 3. Selected hit compound 10-point concentration response in ECM assay. (A) Full-plate montage of fibronectin staining 
showing 10-point concentration response of 32 compound hits selected from the primary screen. Compound names listed, with 
the most active compounds highlighted in red. (B) Concentration responses of fibronectin deposition and cytotoxicity for the six 
compounds that reduced ECM deposition in a concentrated-related manner (see Suppl. Figs. S1–S3 for collagen I+III and IV data). 
Conc., concentration.
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apoptosis was monitored over the following 48 h using a 
caspase 3/7 biosensor and an IncuCyte Zoom microscope. 
Assessment of caspase 3/7 activation over the 48 h period 
after compound addition showed that all but two compounds 
(camptothecin and niclosamide) induced little or no apopto-
sis over DMSO control (Fig. 4C). The apoptosis induced by 
camptothecin and niclosamide was largely seen at higher 
concentrations (1–10 µM), indicating that even with these 
compound hits there may be a potential therapeutic window 
where ECM deposition and αSMA expression are reduced at 
lower doses with minimal effect on cell death.
Inhibition of Scratch Wound Migration in Primary Lung Fibro-
blasts. Primary lung fibroblasts were seeded in 96-well 
plates at a density of 15,000 cells/well to create a confluent 
monolayer. Twenty-four hours after cell plating, the Incu-
Cyte WoundMaker device was used to create a homoge-
neous scratch wound in each well of the 96-well plate. The 
IncuCyte Zoom was used to monitor fibroblast migration 
into the wound every 2 h. Images were analyzed using the 
IncuCyte Zoom Scratch Wound analysis module measuring 
the relative wound confluence over time. None of the six 
selected hit compounds showed a concentration-dependent 
change in the ability of the fibroblasts to migrate into the 
wound site of the scratch wound assays, with a reduction 
seen only at the highest concentrations (3–10 µM) (Fig. 
4D). It is therefore likely that none of the compounds have 
a significant effect on primary human fibroblast cell 
migration.
Structural Similarity Ligand-Based Target Predictions (SEA 
Search). Although the six hit molecules have annotated pro-
tein targets, the promiscuous biological activity of most 
chemical compounds18,19 should be taken into account since 
the observed phenotype could be attributed to an unidenti-
fied target, unrelated to toxic liabilities. In order to investi-
gate this, we performed ligand and structure based in silico 
search of the most potent hits. SEA search (http://sea.bkslab.
org)13 utilizes a SMILES string to search the pharmacologi-
cal space around a chemical structure to predict and rank 
possibly unexpected protein targets for the query molecule. 
The SEA output includes an output ranking the proposed tar-
get/query interaction by probability (significant, p ≤ 10–15; 
highly significant, p ≤ 10–40) and by similarity score to an 
annotated compound/drug (Tanimoto coefficient, max Tc 
≥ 0.40, max Tc 1.0 = exact match).14 The SEA output (Fig. 
5) for our hit compounds was potentially informative in 
identifying additional potential targets for our most potent 
hit, niclosamide (KCNMA1 and TMPRSS4), as well as 
GSK-650394 (CAMKK2, AXL, RIPK1). Four of the hits 
(RepSox, fenretinide, camptothecin, and diphenylene-iodo-
nium chloride) did not produce significant SEA predictions 
beyond their known targets (Fig. 6).
Network Analysis of Hit Compounds. Network analysis using 
the STITCH-STRING database of protein–chemical inter-
actions was used to identify and visualize the target protein 
networks of the six hit compounds (Fig. 7A). GSK-650394 
Figure 4. Secondary hit triage assays. (A) Concentration 
response of the six hit compounds on αSMA expression 
measured as a percentage of TGFβ (DMSO) positive control 
(see Suppl. Fig. S4 for representative high-content image).  
(B) Concentration response of the six hit compounds on 
fibroblast proliferation as measured by the percentage of the 
TGFβ (DMSO) positive control. (C) Concentration response 
of the six hit compounds on fibroblast apoptosis at 48 h post-
compound addition as measured by the activation of caspase  
3/7 (see Suppl. Fig. S4 for representative image).  
(D) Concentration response of the six hit compounds on 
scratch wound healing as measured by wound confluence at 24 
h presented as a percentage of DMSO control (see Suppl. Fig. 
S4 for representative image).
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only had STITCH-STRING interaction with its target 
SGK1. Functional analysis of the hit compound protein tar-
gets showed enrichment of pathways regulating maresin 
synthesis, TGFβ receptor signaling, WNT signaling, apop-
tosis, inflammasomes, and transcriptional regulation of plu-
ripotent stem cells (Fig. 7B).
Discussion
The ECM represents a reinforced composite of structural 
proteins (collagen, laminin, fibronectin, etc.) that are orga-
nized as fibrillar structures embedded within a viscoelastic 
gel that consists of proteoglycans, glycoproteins, water, 
growth factors, and other metabolites secreted by cells.20 
The ECM provides both structural support and biochemical 
signals for multicellular tissue and organ systems. The com-
position and structure of the ECM is sensed by cell surface 
receptors such as heterodimeric integrins, cell surface 
glycoproteins such as dystroglycan, and CD44 and receptor 
tyrosine kinases such as the discoidin domain receptor fam-
ily to regulate cell function.21,22 The immune response in the 
lung is fundamentally protective; however, chronic and pro-
gressive lung inflammation can be harmful. Persistent 
release of pro-inflammatory cytokines and chemokines elic-
its a number of aberrant biological responses in the lung, 
including chemotaxis of leukocytes, angiogenic activity, and 
induction of ECM synthesis and cell proliferation, which 
contribute to lung injury and pulmonary fibrosis.23 ECM 
deposition and altered ECM remodeling contribute to a 
decline in tissue elasticity and lung function, and altered 
ECM is considered not only a consequence but also a driver 
of progressive fibrosis. A spectrum of increased pulmonary 
fibrogenesis is observed in patients with COVID-19 from 
both nonventilated and mechanically ventilated patients, and 
in fatal cases of COVID-19, pulmonary fibrosis is generally 
present at autopsy.1–3 Recent proteomic studies indicate 
Figure 5. SEA search of hit compounds GSK-650394 and niclosamide to predict polypharmacology. Output compound structural 
similarity to query hit compound depicted in red. Prediction power indicated by probability (significant, p ≤ 10–15; highly significant, 
p ≤ 10–40) and Tanimoto coefficient (max Tc ≥ 0.4, 0 ≤ Tc ≤ 1.0). CAMKK2, calcium/calmodulin-dependent protein kinase kinase 
2; AXL, tyrosine kinase receptor UFO; RIPK, receptor-interacting serine/threonine protein kinase; KCNMA1, calcium-activated 
potassium channel subunit alpha-1; TMPRSS4, transmembrane protease serine 4.
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significant changes in the composition and expression of 
multiple proteins associated with ECM homeostasis in the 
lungs of patients with COVID-19.24
Altered ECM deposition and remodeling therefore 
appear to represent a key pathological feature of lung fibro-
sis and a potential therapeutic target to prevent, delay, or 
alleviate long-term morbidity and mortality. Traditional 
approaches for quantifying ECM production and turnover 
within in vitro assays include the incorporation and release 
of radiolabeled amino acids.25,26 However, these assays are 
technically challenging and not amenable to automated 
high-throughput screening. The development of the “Scar-
in-a-Jar” model of fibrosis enabled optical image-based 
analysis of both fibroblast cell phenotypes and ECM depo-
sition in each well of a 24-well assay plate.27 Holdsworth 
et al. developed this assay concept further using an in vitro 
model of renal epithelial cells that, following TGFβ stimu-
lation of ECM synthesis, are lysed prior to fixation, 
immunostaining, and high-content image analysis of ECM 
deposition in 96- and 384-well plates.10 We further adapted 
this assay to monitor the deposition of the ECM proteins; 
collagen types I, III, and IV; and fibronectin in primary 
human lung fibroblasts cultured in 384-well plate formats. 
Following screening, multiparametric high-content analysis 
of ECM deposition, and hit confirmation, we identified the 
following six small-molecule drugs with potent activity 
upon inhibiting ECM deposition: RepSox, niclosamide, 
GSK-650394, fenretinide, camptothecin, diphenylene-
iodonium chloride.
GSK-650394 is annotated as an antagonist for serum- and 
glucocorticoid-regulated kinase 1/2 (SGK1/2) and calcium/
calmodulin-dependent kinase kinase 2 (CAMKK1/2).28,29 The 
SEA search in fact indicated a high degree of similarity and 
significance to multiple kinases based on its 3,5-diphenyl-
1H-pyrrolo[2,3-b]pyridine core structure, including AXL 
receptor tyrosine kinase30 and RIPK1 (receptor-interacting 
Figure 6. SEA search of hit compounds RepSox, fenretinide, camptothecin, and diphenylene-iodonium chloride to predict 
polypharmacology. Output compound structural similarity to query hit compound depicted in red. Prediction power indicated by 
probability (significant, p ≤ 10–15; highly significant, p ≤ 10–40) and Tanimoto coefficient (max Tc ≥ 0.4, 0 ≤ Tc ≤ 1.0). TGFBR1, 
TGFβ receptor type I; RBP4, retinol-binding protein 4; SLC47A2, multidrug and toxin extrusion protein 2; N/A, not applicable (no 
significant predictions found).
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serine/threonine-protein kinase 1)31 (Fig. 5). Although all the 
above targets are expressed in the lung (medium to high 
expression) (https://www.proteinatlas.org/), SGK1 overex-
pression has previously been implicated to play a role in 
inflammation resolution,32 pulmonary fibrosis,33 and fibro-
nectin formation in other fibrotic diseases.34 Therefore, SGK1 
would appear to be a bona fide target in our model system; 
however, the effect of GSK-650394 on other targets cannot be 
ruled out.
Niclosamide, our most potent hit on the fibronectin 
deposition assay (~60 nM) (Fig. 3B), generated some 
potentially interesting SEA outputs. Originally used in the 
treatment of tapeworm, niclosamide is also active against 
STAT3 at micromolar concentrations, and the JAK2/STAT3 
pathway has been shown to be active in IPF.35 Niclosamide 
has also been shown to have anti-inflammatory and bron-
chodilation properties via TMEM16A antagonism36 and has 
been investigated for activity against SARS-COV (2007)37 
while currently being reinvestigated for SARS-COV-2 
(NCT04399356) with a view to reformulation as an aerosol 
for respiratory tract drug delivery.38 Although these latter 
activities refer to effects on viral replication and αSMA 
expression, combined with the SEA search output, they 
suggest that niclosamide is antagonistic against a number of 
targets that, potentially, all contribute to the phenotypes 
observed. The two most significant predictions from the 
SEA search for targets of niclosamide include KCNMA1 
(calcium-activated potassium channel subunit alpha-1) and 
TMPRSS4 (transmembrane protease serine 4) (Fig. 5), both 
of which have been associated with pulmonary fibrosis. 
KCNMA1 is the main subunit forming the large-conductance 
potassium channel (BK channel), the activity of which is 
elevated in fibroblasts from patients with IPF and can affect 
the expression of αSMA by increasing intracellular cal-
cium, required for myofibroblast differentiation leading to 
lung fibrosis.39 TMPRSS4 is similarly upregulated in IPF,40 
Figure 7. Network analysis of antifibrotic compounds. (A) Proteins (red circles) interacting with hit compounds (white boxes) 
were identified using the STITCH-STRING database of protein–protein interactions. Edge thickness denotes the STRING confidence 
score (thicker higher confidence). (B) ClueGO functional analysis of hit compound networks using Reactome pathways (p < 0.05, 
Bonferroni step-down correction). Greater node size denotes greater significance.
Marwick et al. 13
and its possible inhibition by niclosamide could have an 
effect in vivo; however, it is not reported to be expressed in 
lung fibroblasts40 and thus is unlikely to be relevant in our 
cell-based model. TMPRSS4 has been linked with SARS-
COV-2 cell entry and infection of several host cell types.41,42 
Published studies and our network analysis (Fig. 7) indicate 
niclosamide also inhibits the WNT signaling pathway,43 and 
WNT signaling has previously been implicated in lung 
fibrosis.44 Therefore, the unique polypharmacology proper-
ties of niclosamide may provide added benefit to COVID-
19 patients by targeting distinct mechanisms associated 
with SARS-COV-2 infection and lung fibrosis. Overall, the 
low nanomolar concentration of niclosamide required to 
decrease ECM deposition and αSMA expression (Figs. 3B 
and 4A) combined with relatively low toxicity and apopto-
sis induction at concentrations <100 nM (Fig. 4B–D) 
makes a strong case for further investigation in all stages of 
COVID-19.
Of the remaining hits from our screen, RepSox anti-
TGFβ pathway activity is clearly an established target for 
lung fibrosis;45,46 however, clinical trials of small-molecule 
and biological inhibitors of TGFβ signaling have not 
resulted in approved therapeutics.47 Fenretinide, a synthetic 
retinoid, has mainly been investigated in an anticancer con-
text but also has anti-inflammatory and antiviral proper-
ties.48 Fenretinide has been demonstrated to exhibit 
antifibrotic properties in hepatic fibrosis models where the 
mechanism of action is thought to be mediated via reactive 
oxygen species (ROS) generation and hepatic stellate cell 
apoptosis.49 Its drug development has been inhibited by its 
poor oral bioavailability requiring new formulations50  
and, interestingly, has recently been suggested as an adju-
vant for COVID-19 treatment via pulmonary delivery.51 
Camptothecin, a well-characterized antineoplastic agent 
targeting DNA topoisommerase I, has been reported as 
modulating HIF1α activity and hence inflammation,52 
implying a potential antifibrotic role. Camptothecin has 
also been previously shown to inhibit collagen I deposition 
in activated dermal fibroblasts.53 However, camptothecin 
itself has been superseded in the clinic by irinotecan and 
topotecan, and both compounds were inactive in our ECM 
deposition readouts, so the relevance of this drug class in 
lung fibrosis remains to be determined. Finally, diphenyl-
ene-iodonium chloride is a seemingly unremarkable, hyper-
valent organoiodine compound and is the least active of our 
validated hits (EC50 4.2 µM fibronectin deposition) (Fig. 
3B). Nevertheless, it has been reported as attenuating IPF-
associated senescent lung fibroblasts and TGFβ-induced 
peroxide formation via inhibition of NADPH oxidases 
(NOX).54,55 More specifically, diphenylene-iodonium chlo-
ride has been shown to protect from bleomycin-induced 
lung fibrosis in vivo, quantified in part by reduction of 
αSMA-expressing myofibroblasts, through inhibition of 
NOX4.56 The activity of diphenylene-iodonium chloride 
includes flavoenzymes in general,57 as well as a broad-spectrum 
bacteriocide.58 It is currently in unrelated clinical trials for 
motion sickness, formulated as a nasal gel (DPI-386, 
NCT04184115, phase 3), but is otherwise an unapproved 
drug and any utility in COVID-19-related fibrosis remains 
to be determined. Protein interaction network analysis per-
formed on our confirmed hit compounds has identified sev-
eral other pathway and protein targets potentially implicated 
in the pharmacological responses observed in our pheno-
typic lung assays, including maresin synthesis, WNT sig-
naling, apoptosis, inflammasomes, and stem cell 
transcriptional regulation (Fig. 7). Mapping of these path-
ways to drug target databases and further experimental 
investigation may reveal additional drug repurposing 
opportunities in lung fibrosis.
There are only two drugs approved for specifically treat-
ing IPF, pirfenidone and nintedanib. These have proven par-
tially effective at controlling lung diseases such as IPF, and 
studies are ongoing as to their effectiveness toward the 
fibroproliferative response in COVID-19.1 However, stan-
dard oral administration of pirfenidone and nintedanib 
would be unsuitable for patients on a ventilator, and thus 
other formulations and administration routes would be 
required. The use of pirfenidone and nintedanib for effec-
tive treatment of lung fibrosis is also limited by their 
potency and selectivity; while they have both been proven 
effective in reducing functional decline and disease pro-
gression in IPF, neither represents a cure, and most patients 
continue to progress despite treatment. Pirfenidone was 
present in LOPAC and was not classed as a hit at the 1 µM 
concentration tested in our screen. This was not surprising, 
as previous studies have reported in vitro activity of pirfeni-
done in the millimolar range.59,60 Nintedanib was not pres-
ent in our screening library; it is a multitarget kinase 
inhibitor and has previously been implicated in perturbing 
multiple cellular functions, including ECM deposition, cell 
proliferation, migration, and apoptosis.61–64 It therefore 
remains to be determined if nintedanib would be classed as 
a hit in our screen using our criteria of selective inhibition 
of ECM deposition independent of overt cell death. 
However, the purpose of our high-content lung fibroblast 
ECM deposition screen and suite of secondary assays is to 
identify potent and selective drug repurposing opportunities 
and new drug discovery programs that provide improve-
ments over the existing agents currently used for IPF.
Guided by the phenotypic screening “rule of 3”—(1) rel-
evant/primary human cell type, (2) disease-relevant stimu-
lus, and (3) assay readout proximity to the clinical 
endpoint65—we describe a high-throughput lung fibroblast 
ECM deposition assay in 384-well plate format and a cas-
cade of secondary lung fibroblast phenotypic assays to sup-
port the discovery of new therapies for tackling lung 
fibrosis. The foundation of the assay system is cryopre-
served primary human lung fibroblasts subjected to limited 
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in vitro cell culture passage. The primary human lung ECM 
deposition assay uses TGFβ as a pro-fibrotic inflammatory 
stimulus to induce ECM deposition from lung fibroblasts. 
TGFβ has previously been identified as an important pro-
inflammatory agent in fibrosis and has been proposed as a 
potential therapeutic target in COVID-19.45,46,66 The pri-
mary phenotypic screening assay endpoint for hit selection 
includes multiparametric analysis of the deposition of mul-
tiple ECM proteins associated with clinical lung fibrosis, 
including collagens I, III, and IV and fibronectin. A signifi-
cant challenge presented by our cell-free high-content ECM 
deposition assay endpoint is triaging cytotoxic compounds; 
thus, our approach monitors cytotoxicity in the same assay 
wells as those used for the final ECM assay endpoint. In the 
current assay format, cytotoxicity was assessed in live cell 
images using a semiquantitative method of cell confluence 
to highlight potential cytotoxic effects for visual inspection 
and confirmation. This assessment of cytotoxicity in live 
cell assay plates could be improved with more automated 
label-free analysis of cell health using artificial intelligence 
and machine learning-based classification methods.67,68
In this pilot study, our primary screen and secondary 
assays demonstrate high levels of reproducibility and signal 
to noise and have identified highly potent drugs that may 
have potential for drug repurposing opportunities. Our pri-
mary human lung ECM deposition assay and suite of sec-
ondary assays are suitable for high-throughput screening of 
larger diverse chemical libraries and siRNA or CRISPR 
genetic screens. Therefore, the assay protocols, image anal-
ysis, and pathway network analysis tools described in our 
study can be utilized in further small-molecule and function 
genomic phenotypic screens to identify novel chemical 
starting points and/or therapeutic targets to advance drug 
discovery in lung fibrosis.
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